Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Clinical Oncology: Case Reports
Buganegrave; Anna Author
Subjects of specialization
Affiliation
Immune checkpoint inhibitors; Cancer; Diabetes mellitus; Immunotherapy; Immune-related adverse events; Nivolumab; Endocrine adverse events
Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum University of Bologna, Bologna, Italy
Biography
Dr. Buganè Anna is working the field and division of Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda Ospedaliero-Universitaria di Bologna, having specialization in Immune checkpoint inhibitors; Cancer; Diabetes mellitus; Immunotherapy; Immune-related adverse events; Nivolumab; Endocrine adverse events
Publications
Case Report Subscription
Nivolumab Induced A Rapid Onset of Diabetes Mellitus In Patients With Cancer: Three Case Reports
Author(s): Lo Preiato Valentina, Salvagni Stefania, Buganè Anna, Vicennati Valentina, Ardizzoni Andrea, Pagotto Ubert and Pelusi Carla
Background: Immune Checkpoint Inhibitors (CPIs) have been proven to be effective in terms of the response rate and survival of cancer patients. However, these drugs are responsible for several immune related adverse events (irAEs). Among the endocrine irAEs, anti-programmed cell death 1 antibodies have mostly been associated with thyroid dysfunction and recently with many cases of Diabetes Mellitus (DM). We report three cases of DM induced by Nivolumab with similar clinical onsets but different laboratory and presentation timings.
Cases: Of the three patients, two had a diagnosis of advanced melanoma and one of metastatic lung cancer. In all three cases, DM arose suddenly, with polyuria, polydipsia and weight loss. In two patients, DM occurred... view more»
Google Scholars / Researchers Sites
